3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
3
Phase 1/2
3
Phase 1
3
Phase NA
1
Phase 4
1
Status
Completed
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
3
Conditions
Carcinoma, Hepatocellular
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Carcinoma, Renal Cell
7
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Differentiated Thyroid Cancer (DTC)
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Advanced Malignancies
1
Advanced Endometrial Cancer
1
Interventions
Paclitaxel
25
Doxorubicin
15
Carboplatin
14
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Docetaxel
5
Chemotherapy, Adjuvant
5
Taxes
4
Filgrastim
4
Brachytherapy
4
lenvatinib
3
Observation
3
trastuzumab deruxtecan
2
selinexor
2
olaparib
2
durvalumab
2
Tamoxifen
2
Specimen Handling
2
Ifosfamide
2
Drug Therapy
2
sintilimab
1
sacituzumab govitecan
1
pertuzumab
1
nanocis
1
liposomal doxorubicin
1
ixabepilone
1
gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
dostarlimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Endometrial Neoplasms
×
lenvatinib
×
Clear all
NCT03517449
2026-03-19
MK-3475-775
Eisai Inc.
Phase 3
Completed
827 enrolled
34 charts
1 FDA
NCT03884101
2026-02-02
LEAP-001
Merck Sharp & Dohme LLC
Phase 3
Completed
842 enrolled
25 charts
NCT04865289
2025-12-02
LEAP-001
Merck Sharp & Dohme LLC
Phase 3
Completed
130 enrolled
24 charts